Blog

Join Us at WHX Bangkok | Booth L46, Hall 6 Advancing Precision Medicine with Digital PCR Innovation From July 8–10, 2026, the WHX World Health Expo (formerly Asia Health) will take place at the Queen Sirikit National Convention Center in Bangkok, Thailand. TargetingOne will exhibit at Booth L46, Hall 6, presenting its fully automated digital PCR systems and molecular diagnostic solutions. We welcome global partners from clinical diagnostics, research, and distribution to visit us for collaboration discussions. About WHX World Health Expo WHX World Health Expo is a leading medical industry exhibition in Southeast Asia, covering the full healthcare value chain, [...]

2026 CACLP丨TargetingOne invites you to the laboratory expo in Xiamen!

Setting Sail in Dubai, Connecting the World with Intelligence! TargetingOne Debuts at WHX Labs Dubai 2026 On February 13, 2026, the annual grand event in the Middle East's medical laboratory field — WHX Labs Dubai — successfully concluded at the Dubai World Trade Center! The overseas team of TargetingOne Corporation, accompanied by its independently developed digital PCR technology and ultra-multiplex testing solutions, attracted partners from five continents who stopped by for discussions, writing a powerful opening chapter for its 2026 overseas market expansion! At the WHX Labs Dubai 2026 exhibition site, the technical team from Target Biotechnology explained the fully [...]

Join Us at WHX Labs Dubai 2026 | Hosted by TargetingOne 2026 WHX Labs Dubai | Feb 10–13, Dubai World Trade Centre. Discover TargetingOne’s D-Series fully automated digital PCR systems at Booth SA.G09. We warmly welcome your visit and insightful exchanges. D-Series Automatic Digital PCR system on display The TargetingOne D20/D30 fully automated digital PCR system is the "star product" at this exhibition. It integrates droplet generation, PCR amplification, and droplet detection into one. Ultra-multiplex Molecular Solutions TargetingOne will prominently showcase ultra-multiplex detection overall solutions—including for lung cancer, thyroid cancer, sepsis, and NIPT—developed based on the D-Series fully automated digital PCR [...]

Major Breakthrough! TargetingOne's Lung Cancer EGFR Liquid Biopsy Digital PCR Kit Obtains Class III Registration Certificate! On September 2, 2024, the "Human EGFR Gene Mutation Detection Kit (Digital PCR Method)" developed by TargetingOne was approved by the National Medical Products Administration (NMPA). This is another digital PCR diagnostic reagent launched by TargetingOne after its nucleic acid detection reagent for COVID - 19 based on digital PCR technology was approved in 2022. This reagent is used for the companion diagnosis of lung cancer EGFR gene liquid biopsy, representing a significant breakthrough in the research, development, and application of the high - [...]

Major Breakthrough | TargetingOne's Hepatitis B DNA Quantitative Detection Digital PCR Reagent Obtains Class III Registration Certificate! TargetingOne Technology (Beijing) Co., Ltd., a wholly - owned subsidiary of TargetingOne Co., Ltd., had its "Hepatitis B Virus (HBV) Nucleic Acid Detection Kit (Digital PCR Method)" approved as a Class III medical device by the National Medical Products Administration (NMPA). This is another blockbuster Class III diagnostic reagent based on digital PCR technology launched by TargetingOne, following the approval of its nucleic acid detection reagents for COVID - 19 and blood EGFR mutation detection. This kit can directly conduct in - vitro [...]

Milestone! TargetingOne Obtains the First Class III NMPA Certificate for Digital PCR Instrument Recently, the D50 automatic digital PCR instrument independently developed by TargetingOne was approved by the National Medical Products Administration to obtain the Class III medical device registration certificate (Registration No.: 20253220212). This is also the first approved digital PCR instrument platform since the National Medical Products Administration issued a document in March 2022 clearly stating that digital PCR should be managed as Class III medical devices. This breakthrough is of great significance for the practical clinical application of digital PCR technology and can be regarded as an [...]

D2 Digital PCR Platform Obtains Another Class III Certificate: TargetingOne Leads with the Top Two NMPA Class III Certificates for Digital PCR Platforms! Recently, the D2 Digital PCR platform (Digital PCR Droplet Preparation and Analyzer) independently developed by TargetingOne was approved by the National Medical Products Administration (NMPA) to obtain a Class III medical device registration certificate (Registration Certificate No. for Medical Devices in China: 20253220394). This is the second digital PCR instrument product to be approved in just one month after the first approval of the D50 fully automatic digital PCR instrument of TargetingOne! The series of digital PCR [...]

Nucleic acid extraction in molecular diagnostics Molecular diagnosis refers to the application of molecular biology methods outside the human body to detect changes in the structure or expression levels of genetic material in the patient's body, and to obtain clinical diagnostic information by testing human samples (blood, body fluids, tissues, etc.) in order to determine disease or body function. One of the key steps in detecting human samples is the extraction and purification of nucleic acids (DNA and RNA) from the samples, the quality of which directly determines the validity and accuracy of the test results. ​ As a leader in [...]